Valneva SE (EPA: VLA)
France
· Delayed Price · Currency is EUR
2.122
+0.050 (2.41%)
Jan 20, 2025, 5:35 PM CET
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
€234,519
Profits / Employee
€10,973
Market Cap
344.55M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sanofi | 86,088 |
EssilorLuxottica Société anonyme | 151,292 |
Sartorius Stedim Biotech | 10,662 |
bioMérieux | 13,982 |
Ipsen | 5,325 |
Eurofins Scientific SE | 61,798 |
Virbac | 5,459 |
Ramsay Générale de Santé | 34,218 |
Valneva SE News
- 14 days ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 6 weeks ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 6 weeks ago - Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults - Benzinga
- 7 weeks ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 7 weeks ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 2 months ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 2 months ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire